| 2025-11-14 |
详情>>
股本变动：
变动后总股本524.38万股
|
| 2025-11-14 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-2.28美元,归母净利润-578.13万美元,同比去年增长11.50%
|
| 2025-11-12 |
股东大会：
将于2025-12-30召开股东大会
会议内容 ▼▲
- 1.To elect the two Class III directors to the Board to serve until the 2028 Annual Meeting of Stockholders and until their respective successors are elected and qualified, or until their earlier death, resignation or removal ("Proposal 1");
2.To ratify of the selection of CBIZ CPAs P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 ("Proposal 2");
3.Ratify, by a vote of all the stockholders, the issuance of the Private Placement Warrants and the issuance of up to 648,148 shares of Class A Common Stock upon the exercise of the Private Placement Warrants issued as part of the Armistice SPA, in accordance with Nasdaq Listing Rule 5635(d)) (“Proposal 3”).;
4.To transact any other business that properly comes before the Annual Meeting and any adjournment or postponement of the Annual Meeting.
|
| 2025-09-24 |
复牌提示：
2025-09-24 10:30:06 停牌，复牌日期 2025-09-24 10:35:06
|
| 2025-08-14 |
详情>>
业绩披露：
2025年中报每股收益-1.57美元,归母净利润-386.93万美元,同比去年增长26.67%
|
| 2025-05-21 |
详情>>
内部人交易：
Genner Gareth Neville共交易2笔
|
| 2025-05-15 |
详情>>
业绩披露：
2025年一季报每股收益-0.89美元,归母净利润-215.74万美元,同比去年增长19.46%
|
| 2025-03-31 |
详情>>
业绩披露：
2024年年报每股收益-11.36美元,归母净利润-1254.46万美元,同比去年增长-64.25%
|
| 2025-03-28 |
股东大会：
将于2025-05-15召开股东大会
会议内容 ▼▲
- 1.Ratify, by a vote of all the stockholders, the approval of the issuance of, and the issuance of shares upon the exercise of, certain common stock purchase warrants consisting of Series A common warrants exercisable for up to 370,370 shares of Class A Common Stock at an exercise price of $8.10 per share of Class A Common Stock (the “Series A Warrants”), and Series B common warrants exercisable for up to 277,778 shares of Class A Common Stock at an exercise price of $8.10 per share (the “Series B Warrants”, and collectively with the Series A Warrants, the “Private Placement Warrants”) issued pursuant that certain Securities Purchase Agreement dated December 5, 2024 between our Company and Armistice Capital Master Fund Ltd. (the “Armistice SPA”), as required by and in accordance with Nasdaq Listing Rule 5635(d));
2.To transact any other business that properly comes before the Special Meeting and any adjournment or postponement of the Special Meeting.
|
| 2025-01-04 |
详情>>
拆分方案：
每15.0000合并分成1.0000股
|
| 2024-12-26 |
股东大会：
将于2025-02-07召开股东大会
会议内容 ▼▲
- 1.Ratify, by a vote of all the stockholders, the approval of the issuance of, and the issuance of shares upon the exercise of, certain common stock purchase warrants consisting of Series A common warrants exercisable for up to 5,555,548 shares of Class A Common Stock at an exercise price of $0.54 per share of Class A Common Stock (the “Series A Warrants”), and Series B common warrants exercisable for up to 4,166,661 shares of Class A Common Stock at an exercise price of $0.54 per share (the “Series B Warrants”, and collectively with the Series A Warrants, the “Private Placement Warrants”) issued pursuant that certain Securities Purchase Agreement dated December 5, 2024 between our Company and Armistice Capital Master Fund Ltd. (the “Armistice SPA”), as required by and in accordance with Nasdaq Listing Rule 5635(d));
2.To transact any other business that properly comes before the Special Meeting and any adjournment or postponement of the Special Meeting.
|
| 2024-12-12 |
股东大会：
将于2025-01-29召开股东大会
会议内容 ▼▲
- 1.To elect Class II directors to the Board of Directors (the “Board”) to serve until the 2027 Annual Meeting of Stockholders and until their respective successors are elected and qualified, or until their earlier death, resignation or removal;
2.To ratify the selection of Marcum LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024;
3.To transact any other business that properly comes before the Annual Meeting and any adjournment or postponement of the Annual Meeting.
|
| 2024-11-21 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.49美元,归母净利润-653.28万美元,同比去年增长-37.45%
|
| 2024-09-30 |
股东大会：
将于2024-11-18召开股东大会
会议内容 ▼▲
- 1.Ratify, by a vote of all the stockholders, the approval of that certain Securities Purchase Agreement dated July 13, 2024 between our Company and DQI Holdings, Inc. (the “DQI SPA”) and all transactions contemplated thereunder, including, but not limited to, the sale of 4,597,701 shares of our Class A Common Stock, par value $0.01 per share (“Class A Common Stock”) to DQI as required by and in accordance with Nasdaq Listing Rule 5635(d));
2.Ratify, by a vote of all the stockholders, the approval of the issuance of certain Private Placement Warrants issued pursuant that certain Securities Purchase Agreement dated September 4, 2024 between our Company and Armistice Capital Master Fund Ltd. (the “Armistice SPA”) exercisable for an aggregate of up to 2,865,798 shares of Class A Common Stock, at an exercise price of $0.3223 per share of Class A Common Stock (the “Private Placement Warrants”), as required by and in accordance with Nasdaq Listing Rule 5635(d));
3.Approve the issuance of up to 9,546,060 shares of our Common Stock upon the exercise of certain warrants (the “New Warrants”) issued to Armistice Capital Master Fund Ltd. pursuant to that certain Warrant Exercise Agreement dated September 3, 2024 (the “WEA”) as required by and in accordance with Nasdaq Listing Rule 5635(d));
4.To approve a reverse stock split of our Common Stock, par value $0.01 per share (“Common Stock”), at a ratio of not less than 1-for-5 and not more than 1-for-50, with such ratio to be determined by the Board of Directors on or prior to December 31, 2024, in its sole discretion, and which would be effected by filing a Certificate of Amendment to the Company's Third Amended and Restated Certificate of Incorporation with the State of Delaware (collectively, the “Reverse Split ”);
5.To transact any other business that properly comes before the Special Meeting and any adjournment or postponement of the Special Meeting.
|
| 2024-08-13 |
详情>>
业绩披露：
2024年中报每股收益-0.47美元,归母净利润-527.69万美元,同比去年增长-11.85%
|
| 2024-05-16 |
详情>>
业绩披露：
2024年一季报每股收益-0.26美元,归母净利润-267.86万美元,同比去年增长-5.15%
|
| 2024-04-01 |
详情>>
业绩披露：
2023年年报每股收益-1.07美元,归母净利润-763.76万美元,同比去年增长36.83%
|
| 2024-02-01 |
股东大会：
将于2024-03-20召开股东大会
会议内容 ▼▲
- 1.Approve the issuance of up to 3,600,000 shares of our Common Stock upon the exercise of certain warrants issued to an institutional investor pursuant to that certain Warrant Exercise Agreement dated December 21, 2023 as required by and in accordance with Nasdaq Listing Rule 5635(d));
2.To transact any other business that properly comes before the Special Meeting and any adjournment or postponement of the Special Meeting.
|
| 2023-11-09 |
股东大会：
将于2023-12-29召开股东大会
会议内容 ▼▲
- 1.Items of Business (1) To elect Class I directors to the Board of Directors (the “Board”) to serve until the 2026 Annual Meeting of Stockholders and until their respective successors are elected and qualified, or until their earlier death, resignation or removal;
2.To ratify the selection of Marcum LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023;
3.To transact any other business that properly comes before the Annual Meeting and any adjournment or postponement of the Annual Meeting.
|
| 2023-11-07 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.71美元,归母净利润-475.3万美元,同比去年增长40.99%
|
| 2023-11-07 |
财报披露：
美东时间 2023-11-07 盘后发布财报
|
| 2023-08-22 |
详情>>
业绩披露：
2023年中报每股收益-0.8美元,归母净利润-471.78万美元,同比去年增长-2.24%
|
| 2023-04-13 |
股东大会：
将于2023-05-13召开股东大会
会议内容 ▼▲
- 1.Approval of the second amended and restated certificate of incorporation
2.Ratification of the reverse split
|
| 2023-03-23 |
详情>>
拆分方案：
每5.0000合并分成1.0000股
|
| 2022-10-28 |
股东大会：
将于2022-12-15召开股东大会
会议内容 ▼▲
- 1.To elect eight directors to the Board of Directors (the “Board”) to serve until the 2023 Annual Meeting of Stockholders and until their respective successors are elected and qualified;
2.To approve an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, to increase the authorized Common Stock of the Company from 37,500,000 shares to 50,000,000, thereby increasing the total authorized capital stock of the Company from 39,500,000 shares to 52,000,000 shares, consisting of 50,000,000 shares of Common Stock and 2,000,000 shares of Preferred Stock);
3.To transact any other business that properly comes before the Annual Meeting and any adjournment or postponement of the Annual Meeting.
|